Etanercept as prophylactic psoriatic therapy before interferon-α and ribavirin treatment for active hepatitis C infection

Behnam, Shahdad E; Hindiyeh, Rasha; Fife, Douglas; Jeffes, Edward W. B.; Wu, Jashin J.

doi:10.1111/j.1365-2230.2009.03476.x

Cited by 24 publications

(21 citation statements)

References 6 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, another report of five patients receiving etanercept described increased viral replication in two patients, neither of whom was on antiviral prophylaxis [134] . Etanercept has been used successfully as prophylaxis against psoriasis in chronic hepatitis C patients undergoing IFN therapy [135] . It should be noted, however, that exacerbation of IBD has been reported with IFN therapy, requiring its discontinuation [136] .…”

Section: Hepatic Injury From Reactivation Of Viral Hepatitis On Ibd Tmentioning

confidence: 99%

Hepatotoxicity of Agents Used in the Management of Inflammatory Bowel Disease

Khokhar

Lewis²

2010

Dig Dis

View full text Add to dashboard Cite

Patients with inflammatory bowel disease (IBD) are at risk for hepatobiliary disease and toxicity, and the diagnosis of drug-induced liver disease in patients being treated for IBD can represent a clinical challenge. There are a number of disease states associated with IBD, which are primary sclerosing cholangitis, cholangiocarcinoma and autoimmune hepatitis. There is a wide spectrum of hepatic injury that can occur from the agents used to treat IBD, such as acute or chronic hepatic injury directly attributable to the drugs used to treat IBD (e.g. sulfasalazine, mesalamine, thiopurines, methotrexate, TNF antagonists, quinolone antibiotics); liver toxicity from drugs used to treat complications of immunomodulators and TNF antagonists (e.g. isoniazid for treatment of reactivation tuberculosis), and exacerbation of underlying chronic viral hepatitis with infliximab and other TNF antagonists. Thiopurines are also associated with the development of hepatic vascular lesions, such as nodular regenerative hyperplasia and peliosis hepatic. In addition, biologics can be associated with the reactivation of underlying chronic viral hepatitis, mandating universal screening prior to initiation of TNF-alpha antagonist therapy.

show abstract

Section: Hepatic Injury From Reactivation Of Viral Hepatitis On Ibd Tmentioning

confidence: 99%

Hepatotoxicity of Agents Used in the Management of Inflammatory Bowel Disease

Khokhar

Lewis²

2010

Dig Dis

View full text Add to dashboard Cite

show abstract

“…Etanercept has been shown to be safe in combination with interferon and ribavirin 8. However, only two published cases have described the concomitant use of IFN and etanercept in a patient with chronic HCV monoinfection and rheumatoid arthritis or psoriasis, respectively 9 10. In our patient previous Peg-IFN/ribavirin treatment without concomitant TNFα therapy failed due to an exacerbation of psoriatic arthritis.…”

mentioning

confidence: 75%

Successful clearance of hepatitis C virus with pegylated interferon -2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis

Mederacke

Witte

Wedemeyer

2010

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

“…10 In addition, anti-TNF-a therapy did not alter liver histology in two patients with HCV who received etanercept for psoriasis. 13 The use of etanercept in one case led to a marked decrease in HCV viral load and a reduction in liver enzymes, with significant improvement in psoriasis. 12 Etanercept has been used successfully as a prophylactic psoriatic therapy before interferon-a and ribavirin treatment for active HCV infection.…”

Section: Discussionmentioning

confidence: 98%

“…11 Treatment of HCV infection with interferon can induce psoriatic flares. 13 The Royal College of General Practitioners (RCGP) recommends HCV screening for those with established risk factors for infection, including asymptomatic individuals. 13 The use of etanercept in one case led to a marked decrease in HCV viral load and a reduction in liver enzymes, with significant improvement in psoriasis.…”

Section: Discussionmentioning

confidence: 99%

Is universal screening for hepatitis C infection prior to commencing antitumour necrosis factor-α therapy necessary?

et al. 2013

View full text Add to dashboard Cite

There were no cases of active HCV infection diagnosed through pretreatment anti-TNF-α screening in our department, which is located in a low-prevalence area for HCV infection. In view of the lack of evidence of harm associated with anti-TNF-α use in HCV-infected patients, we propose that screening for HCV infection in low-prevalence areas should be targeted to those with pre-existing risk factors. This is consistent with current guidelines from the Royal College of General Practitioners. Targeted screening rather than universal screening may be a safe and cost-effective option among patients being evaluated for anti-TNF-α therapies.

show abstract

Etanercept as prophylactic psoriatic therapy before interferon-α and ribavirin treatment for active hepatitis C infection

Cited by 24 publications

References 6 publications

Hepatotoxicity of Agents Used in the Management of Inflammatory Bowel Disease

Hepatotoxicity of Agents Used in the Management of Inflammatory Bowel Disease

Successful clearance of hepatitis C virus with pegylated interferon -2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis

Is universal screening for hepatitis C infection prior to commencing antitumour necrosis factor-α therapy necessary?

Contact Info

Product

Resources

About